| Literature DB >> 22721353 |
Per Sjögren1, Justo Sierra-Johnson, Lena V Kallings, Tommy Cederholm, Maria Kolak, Mats Halldin, Kerstin Brismar, Ulf de Faire, Mai-Lis Hellénius, Rachel M Fisher.
Abstract
BACKGROUND: A sedentary lifestyle predisposes to cardiometabolic diseases. Lifestyle changes such as increased physical activity improve a range of cardiometabolic risk factors. The objective of this study was to examine whether functional changes in adipose tissue were related to these improvements.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22721353 PMCID: PMC3475078 DOI: 10.1186/1476-511X-11-80
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Baseline characteristics and follow-up changes of selected variables
| | |||||
|---|---|---|---|---|---|
| Age (yr) | 67.5 (0.5) | 67.6 (0.5) | - | - | |
| Female (%) | 58 | 63 | - | - | |
| Exercise time (min/w) | 120 (5, 205) | 135 (40, 215) | 0 (-105, 240) | +137 (0, 490)** | 0.03 |
| Steps per day | 5200 (2730) | 5900 (2800) | +719 (2490) | +1190 (3270) | 0.28 |
| Dietary improvements (%)c | - | - | 12 | 49 | 0.001 |
| Weight (kg) | 89 (81, 95) | 82 (73, 97) | -0.1 (-1.1, 0.9) | -1.8 (-3.9, 0.3)** | 0.02 |
| BMI (kg/m2) | 30.3 (28.6, 31.8)†† | 27.5 (26.6, 30.8) | -0.04 (-0.47, 0.30) | -0.68 (-1.21, 0.11)** | 0.04 |
| Waist circumference (cm) | 107 (8)† | 103 (10) | -1.3 (3.1)** | -2.6 (4.0)** | 0.12 |
| Body fat mass (kg) | 31.4 (28.1, 38.7)† | 29.8 (24.7, 31.6) | -0.5 (-1.9, 0.4)* | -1.5 (-3.6, -0.4)** | 0.04 |
| Systolic blood pressure (mmHg) | 144 (17) | 136 (16) | -5 (11)* | -0 (15) | 0.61 |
| Diastolic blood pressure (mmHg) | 81 (9) | 78 (10) | -1 (8) | -1 (9) | 0.61 |
| Insulin (uU/mL) | 10.9 (6.8, 14.1)† | 8.2 (6.4, 10.9) | -0.85 (-2.98, 0.89) | -0.90 (-2.97, 0.46)* | 0.16 |
| Glucose (mmol/L) | 5.4 (4.9, 5.7) | 5.3 (4.9, 5.5) | -0.2 (-0.4, 0.1)** | -0.1 (-0.3, 0.1) | 0.79 |
| HOMA | 2.6 (1.7, 3.6)† | 1.9 (1.7, 2.3) | -0.2 (-0.9, 0.3) | -0.2 (-0.7, 0.1) | 0.19 |
| HbA1c (%) | 4.8 (4.6, 5.0) | 4.9 (4.7, 5.2) | 0.1 (0.0, 0.3)** | -0.1 (-0.2, 0.1) | 0.0003 |
| Triacylglycerol (mmol/L) | 1.2 (1.0, 1.6) | 1.1 (1.0, 1.5) | -0.0 (-0.3, 0.2) | -0.1 (-0.3, 0.1)* | 0.23 |
| Cholesterol (mmol/L) | 5.6 (0.9) | 5.9 (1.0) | 0.0 (0.6) | -0.3 (1.0) | 0.14 |
| HDL (mmol/L) | 1.7 (1.4, 1.9) | 1.7 (1.5, 1.9) | -0.1 (-0.1, 0.1) | +0.0 (-0.2, 0.2) | 0.57 |
| ApoB/A1 | 0.73 (0.14) | 0.78 (0.20) | -0.04 (0.11)* | -0.08 (0.15)** | 0.27 |
| C-reactive protein (mg/L) | 1.9 (1.1, 4.0) | 1.7 (0.8, 3.4) | +0.2 (-0.4, 1.5) | +0.1 (-0.7, 0.6) | 0.20 |
| Adiponectin (mg/L) | 16 (10, 21) | 20 (14, 24) | -0.1 (-1.5, 1.3) | +0.3 (-1.0, 1.3) | 0.21 |
| Leptin (ng/mL) | 22 (13, 36) | 15 (13, 23) | -1.1 (-5.0, 0.5) | -1.8 (-8.8, 0.3) ** | 0.011 |
Values are mean (SD) or median (IQR) and changes denote measure(follow-up) – measure(baseline).
Total number of individuals analysed varies slightly due to technical reasons.
a Significant differences between groups at baseline: †P < 0.05, ††P < 0.01.
b Significant within-group changes: *P < 0.05,**P < 0.01.
c Defined as changes (according to self-reported frequencies) in the consumption of at least three of the following dietary variables: vegetables, fruit, seafood, candy, buns, snacks, high fat cheese, pizza and soda.
HOMA, homeostasis model assessment of insulin resistance; HDL, high density lipoprotein; ApoB/A1, ratio between apolipoproteins B and A1.
Baseline values and follow-up changes of fatty acids in subcutaneous adipose tissue
| | |||||
|---|---|---|---|---|---|
| | | | | | |
| Saturated | 30.4 (2.9) | 31.0 (3.7) | -0.3 (1.3) | -0.2 (1.4) | 0.48 |
| Monounsaturated | 57.0 (2.7) | 56.5 (3.7) | +0.3 (1.3) | +0.1 (1.5) | 0.33 |
| Polyunsaturated w6 | 10.6 (9.4, 11.9) | 10.4 (9.7, 11.3) | +0.1 (-0.2, 0.3) | +0.2 (-0.0, 0.5)** | 0.04 |
| Polyunsaturated w3 | 2.0 (0.4) | 2.0 (0.5) | +0.0 (0.2) | -0.0 (0.1) | 0.24 |
| | | | | | |
| 14:0 | 3.3 (0.5) | 3.4 (0.7) | -0.10 (0.20)** | -0.11 (0.24)* | 0.90 |
| 15:0 | 0.33 (0.06) | 0.35 (0.08) | +0.01 (0.02)** | -0.00 (0.02) | 0.12 |
| 16:0 | 23.1 (2.1) | 23.1 (2.6) | -0.15 (0.89) | +0.01 (0.92) | 0.45 |
| 16:1w7 | 6.4 (1.8) | 5.7 (1.4) | +0.16 (0.68) | +0.04 (0.62) | 0.28 |
| 17:0 | 0.27 (0.24, 0.30) | 0.28 (0.25, 0.33) | +0.02 (-0.01, 0.06)** | +0.00 (-0.04, 0.06) | 0.26 |
| 18:0 | 3.4 (0.7)† | 3.9 (0.9) | -0.08 (0.34) | -0.08 (0.38) | 0.50 |
| 18:1 | 50.6 (1.9) | 50.7 (2.7) | +0.15 (0.88) | +0.06 (1.13) | 0.78 |
| 18:2w6 | 9.6 (8.4, 11.0) | 9.4 (8.7, 10.4) | +0.02 (-0.14, 0.22) | +0.17 (0.03, 0.39)** | 0.012 |
| 18:3w6 | 0.10 (0.09, 0.11) | 0.10 (0.09. 0.11) | +0.01 (0.00, 0.01)** | +0.00 (0.00, 0.01) | 0.26 |
| 18:3w3 | 1.08 (0.24) | 1.04 (0.25) | -0.02 (0.09) | -0.03 (0.10) | 0.47 |
| 20:3w6 | 0.21 (0.17, 0.24) | 0.20 (0.16, 0.24) | -0.01 (-0.03, 0.01)** | -0.01 (-0.02, 0.01) | 0.72 |
| 20:4w6 | 0.43 (0.09) | 0.40 (0.10) | +0.01 (0.05) | +0.01 (0.06) | 0.52 |
| 20:5w3 | 0.16 (0.14, 0.19) | 0.16 (0.14, 0.19) | +0.02 (-0.01, 0.05)** | -0.00 (-0.02, 0.03) | 0.079 |
| 22:4w6 | 0.13 (0.12, 0.17) | 0.14 (0.11, 0.17) | -0.00 (-0.01, 0.01) | -0.00 (-0.01, 0.01) | 0.25 |
| 22:5w3 | 0.39 (0.10) | 0.41 (0.14) | +0.00 (0.03) | -0.01 (0.05) | 0.63 |
| 22:6w3 | 0.39 (0.13) | 0.41 (0.19) | +0.01 (0.05) | +0.00 (0.05) | 0.82 |
| SCD-index (16:1/16:0) | 0.28 (0.08) | 0.26 (0.08) | +0.01 (0.04) | -0.00 (0.04) | 0.13 |
Values are mean ± SD or median (IQR) and changes denote measure(follow-up) – measure(baseline). Fatty acids are presented as relative percentage of fatty acids analysed. Saturated, sum of 14:0, 15:0, 16:0, 17:0 and 18:0; Monounsaturated, sum of 16:1 and 18:1 Polyunsaturated w6, sum of 18:2, 18:3, 20:3, 20:4 and 22:4 (all w6); and Polyunsaturated w3, sum of 18:3, 20:5, 22:5 and 22:6 (all w3).
a Significant differences between groups at baseline: †P < 0.05.
b Significant within-group changes: *P < 0.05,**P < 0.01.
Changes from baseline to follow-up in subcutaneous adipose tissue gene expression
| | | ||
| CD68 | 0 (-39, 59) | -16 (-32, 20) | 0.17 |
| CCL2 | -11 (-25, 66) | -17 (-39, 11) | 0.11 |
| IL-6 | -31 (-56, 7)** | -16 (-62, 30) | 0.87 |
| TNFα | -11 (-57, 38) | -16 (-45, 42) | 0.97 |
| Adiponectin | -34 (-66, 64) | +38 (-42, 59) | 0.35 |
| Leptin | -20 (-54, 195) | +107 (-15, 428) | 0.019 |
| CD36 | -8 (-16, 9) | -10 (-47, 18) | 0.55 |
| LPL | -3 (35, 26) | -24 (-43, 12) | 0.44 |
| PPARγ | -9 (-31, 21) | -11 (-28, 26) | 0.30 |
| 11βHSD1 | -4 (-29, 15) | +3 (-31, 18) | 0.57 |
| SCD | +18 (-49, 109) | -62 (-74, 4) | 0.08 |
| CNR1 | -25 (-70, 70) | -4 (-66, 101) | 0.80 |
| CNR2 | -30 (-83, 96) | -9 (-73, 111) | 0.94 |
a Significant within-group changes indicated: **P < 0.01.
Total number of individuals analysed varies slightly due to technical reasons.
Only percent changes are reported since gene expression is quantified in arbitrary units, absolute quantification is not performed.
11βHSD1: 11β-hydroxysteroid dehydrogenase type 1; CCL2: monocyte chemoattractant protein 1 (MCP-1); CNR1: cannabinoid receptor 1; CNR2: cannabinoid receptor 2; IL-6: interleukin 6; IQR: interquartile range; LPL: lipoprotein lipase; TNFα: tumour necrosis factor α; PPARγ: peroxisome proliferator activated receptor gamma; SCD: stearoyl CoA desaturase.
Linear regression analysis for changes in serum leptin, changes in adipose tissue linoleic acid content, and changes in adipose tissue leptin gene expression in relation to changes in selected variables in control and intervention groups
| | ||||||
| | | | | | | |
| ∆ Exercise time | -0.09 | 0.61 | -0.17 | 0.31 | 0.10 | 0.64 |
| ∆ Weight | 0.63 | <0.0001 | 0.12 | 0.43 | -0.01 | 0.96 |
| ∆ BMI | 0.66 | <0.0001 | 0.10 | 0.54 | 0.00 | 0.99 |
| ∆ Body fat mass | 0.63 | <0.0001 | 0.08 | 0.59 | 0.00 | 0.98 |
| ∆ HbA1c | 0.20 | 0.20 | -0.15 | 0.33 | -0.19 | 0.34 |
| ∆ Linoleic acid | 0.14 | 0.39 | -- | -- | -0.34 | 0.086 |
| ∆ Leptin mRNA | -0.03 | 0.90 | -- | -- | -- | -- |
| | | | | | | |
| ∆ Exercise time | 0.40 | 0.07 | 0.39 | 0.047 | -0.43 | 0.11 |
| ∆ Weight | 0.59 | 0.002 | 0.00 | 0.99 | 0.13 | 0.62 |
| ∆ BMI | 0.57 | 0.003 | -0.01 | 0.94 | 0.17 | 0.51 |
| ∆ Body fat mass | 0.29 | 0.17 | -0.09 | 0.63 | 0.06 | 0.82 |
| ∆ HbA1c | -0.15 | 0.46 | 0.09 | 0.64 | 0.01 | 0.97 |
| ∆ Linoleic acid | 0.30 | 0.15 | -- | -- | -0.46 | 0.06 |
| ∆ Leptin mRNA | -0.32 | 0.27 | -- | -- | -- | -- |
The size of the control and intervention groups is: n = 43 and n = 30 for serum leptin and adipose tissue linoleic acid; and n = 30 and n = 21 for adipose tissue leptin gene expression respectively, but the number of individuals analysed varies slightly due to technical reasons.